Literature DB >> 7339819

Basis for lack of drug susceptibility of atypical mycobacteria.

H L David.   

Abstract

The patterns of multiple-drug resistance of the nontuberculous mycobacteria as judged from population analysis of recent isolates are described. In this article the various possible mechanisms of drug resistance in these mycobacteria (high frequencies of spontaneous mutation, drug-resistance factors, permeability, and exclusion) are analysed in light of current evidence. Epidemiologic and bacteriologic arguments are presented that appear to refute the hypothesis that high frequency of spontaneous mutation and drug-resistance factors explain multiple-drug resistance. Preliminary work suggesting that resistance in nontuberculous mycobacteria may be caused by the failure of antibiotics to reach the cytoplasmic membrane is discussed.

Mesh:

Year:  1981        PMID: 7339819     DOI: 10.1093/clinids/3.5.878

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  22 in total

Review 1.  Drug-resistant tuberculosis: what do we do now?

Authors:  A Telenti; M Iseman
Journal:  Drugs       Date:  2000-02       Impact factor: 9.546

2.  Evaluation of growth promotion and inhibition from mycobactins and nonmycobacterial siderophores (Desferrioxamine and FR160) in Mycobacterium aurum.

Authors:  S Bosne-David; L Bricard; F Ramiandrasoa; A DeRoussent; G Kunesch; A Andremont
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

3.  Susceptibility of Mycobacterium kansasii to ethambutol and its combination with rifamycins, ciprofloxacin and isoniazid.

Authors:  U Hjelm; J Kaustová; M Kubín; S E Hoffner
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-01       Impact factor: 3.267

4.  Action of 1-isonicotinyl-2-palmitoyl hydrazine against the Mycobacterium avium complex and enhancement of its activity by m-fluorophenylalanine.

Authors:  N Rastogi; K S Goh
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

5.  Extracellular and intracellular activities of clarithromycin used alone and in association with ethambutol and rifampin against Mycobacterium avium complex.

Authors:  N Rastogi; V Labrousse
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

6.  A bone marrow-derived murine macrophage model for evaluating efficacy of antimycobacterial drugs under relevant physiological conditions.

Authors:  P S Skinner; S K Furney; M R Jacobs; G Klopman; J J Ellner; I M Orme
Journal:  Antimicrob Agents Chemother       Date:  1994-11       Impact factor: 5.191

7.  Activities of fluoroquinolone, macrolide, and aminoglycoside drugs combined with inhibitors of glycosylation and fatty acid and peptide biosynthesis against Mycobacterium avium.

Authors:  W W Barrow; E L Wright; K S Goh; N Rastogi
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

8.  Mycobacterium avium-intracellulare contamination of mammalian cell cultures.

Authors:  I H Lelong-Rebel; Y Piemont; M Fabre; G Rebel
Journal:  In Vitro Cell Dev Biol Anim       Date:  2008-10-15       Impact factor: 2.416

9.  In vitro activities of free and liposomal drugs against Mycobacterium avium-M. intracellulare complex and M. tuberculosis.

Authors:  R T Mehta; A Keyhani; T J McQueen; B Rosenbaum; K V Rolston; J J Tarrand
Journal:  Antimicrob Agents Chemother       Date:  1993-12       Impact factor: 5.191

10.  Enhancement of drug susceptibility of Mycobacterium avium by inhibitors of cell envelope synthesis.

Authors:  N Rastogi; K S Goh; H L David
Journal:  Antimicrob Agents Chemother       Date:  1990-05       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.